These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15374171)

  • 41. Erythrocyte membrane changes associated with nutrition and aging--the role of plasmalogens.
    Brosche T; Summa JD; Platt D
    Arch Gerontol Geriatr; 1989; 9(3):291-6. PubMed ID: 2640088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia.
    Pappu AS; Illingworth DR; Bacon S
    Metabolism; 1989 Jun; 38(6):542-9. PubMed ID: 2725293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
    Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
    Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial.
    Shidfar F; Homayounfar R; Fereshtehnejad SM; Kalani A
    Arch Med Res; 2009 Jul; 40(5):380-6. PubMed ID: 19766902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.
    Vega GL; Grundy SM
    JAMA; 1990 Dec; 264(21):2759-63. PubMed ID: 2232062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Change of plasmalogen content of red blood cells in myocardial hypoxia and acidosis.
    Osipenko AN
    Acta Cardiol; 2018 Feb; 73(1):61-68. PubMed ID: 28814195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.
    Vega GL; Grundy SM
    JAMA; 1987 Jan; 257(1):33-8. PubMed ID: 3537351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular risk and benefits from antioxidant dietary intervention with red wine in asymptomatic hypercholesterolemics.
    Apostolidou C; Adamopoulos K; Lymperaki E; Iliadis S; Papapreponis P; Kourtidou-Papadeli C
    Clin Nutr ESPEN; 2015 Dec; 10(6):e224-e233. PubMed ID: 28531467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study].
    Forti N; Ramires JA
    Arq Bras Cardiol; 1991 Sep; 57(3):253-61. PubMed ID: 1824203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of alternate-day lovastatin in hypercholesterolemic men.
    Dennis VC; Britton ML; Sirmans SM; Letassy NA; Freeman DA
    Ann Pharmacother; 1997 Jun; 31(6):708-12. PubMed ID: 9184709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation.
    Palomäki A; Malminiemi K; Malminiemi O; Solakivi T
    Arterioscler Thromb Vasc Biol; 1999 Jun; 19(6):1541-8. PubMed ID: 10364087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.
    JAMA; 1988 Jul; 260(3):359-66. PubMed ID: 2898027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversible reduction of phospholipid bound arachidonic acid after low density lipoprotein apheresis. Evidence for rapid incorporation of plasmalogen phosphatidylethanolamine into the red blood cell membrane.
    Engelmann B; Bräutigam C; Kulschar R; Duhm J; Prenner E; Hermetter A; Richter WO; Thiery J; Seidel D
    Biochim Biophys Acta; 1994 Dec; 1196(2):154-64. PubMed ID: 7841179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
    Illingworth DR; Bacon S
    Circulation; 1989 Mar; 79(3):590-6. PubMed ID: 2645064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.
    Illingworth DR; Bacon S; Pappu AS; Sexton GJ
    Atherosclerosis; 1992 Sep; 96(1):53-64. PubMed ID: 1418102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.
    Crook D; Bruce R; Worthington M; Mulcahy D; Patterson D; Wynn V
    Cardiovasc Drugs Ther; 1992 Dec; 6(6):633-9. PubMed ID: 1292582
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
    van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH
    Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis.
    Hussein H; Saheb S; Couturier M; Atassi M; Orsoni A; Carrié A; Therond P; Chantepie S; Robillard P; Bruckert E; Chapman MJ; Kontush A
    J Clin Lipidol; 2016; 10(1):124-33. PubMed ID: 26892129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.